Related Experiment Video
Updated: Jun 9, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells
Arielis Rodríguez-Ulloa1, Yassel Ramos, Jeovanis Gil
1Department of Bioinformatics, Center for Genetic Engineering and Biotechnology, Havana, Cuba. arielis.rodriguez@biocomp.cigb.edu.cu
Abstract:
CIGB-300 is a proapoptotic peptide-based drug that abrogates the CK2-mediated phosphorylation. This peptide has antineoplastic effect on lung cancer cells in vitro and in vivo. To understand the mechanisms involved on such anticancer activity, the NCI-H125 cell line proteomic profile after short-term incubation (45 min) with CIGB-300 was investigated. As determined by 2-DE or 2D-LC-MS/MS, 137 proteins changed their abundances more than 2-fold in response to the CIGB-300 treatment. The expression levels of proteins related to ribosome biogenesis, metastasis, cell survival and proliferation, apoptosis, and drug resistance were significantly modulated by the presence of CIGB-300. The protein translation process was the most affected (23% of the identified proteins). From the proteome analysis of the NCI-H125 cell line, novel potentialities for CIGB-300 as anticancer agent were evidenced.
Insights
CIGB-300, a novel peptide drug, demonstrates anticancer effects by inhibiting CK2 phosphorylation in lung cancer cells. Proteomic analysis revealed significant modulation of proteins involved in key cellular processes, highlighting its potential as an antineoplastic agent.
Area of Science:
- Oncology
- Molecular Biology
- Proteomics
Background:
- CIGB-300 is a peptide-based drug with proapoptotic and antineoplastic properties.
- It functions by inhibiting CK2-mediated phosphorylation, a pathway implicated in cancer progression.
- Previous studies demonstrated its efficacy against lung cancer cells in vitro and in vivo.
Purpose of the Study:
- To investigate the proteomic profile of NCI-H125 lung cancer cells after short-term exposure to CIGB-300.
- To elucidate the molecular mechanisms underlying CIGB-300's anticancer activity.
- To identify novel therapeutic targets and potentialities of CIGB-300.
Main Methods:
- Proteomic analysis using 2-DE (2-dimensional electrophoresis) and 2D-LC-MS/MS (2-dimensional liquid chromatography-tandem mass spectrometry).
- Incubation of NCI-H125 cell line with CIGB-300 for 45 minutes.
- Quantification and identification of differentially expressed proteins.
Main Results:
- Treatment with CIGB-300 resulted in significant changes ( > 2-fold) in the abundance of 137 proteins.
- Key affected pathways included ribosome biogenesis, metastasis, cell survival and proliferation, apoptosis, and drug resistance.
- Protein translation was the most impacted process, with 23% of identified proteins involved.
Conclusions:
- CIGB-300 significantly alters the proteome of lung cancer cells, impacting critical cellular functions.
- The modulation of protein expression provides insights into CIGB-300's anticancer mechanisms.
- These findings support the potential of CIGB-300 as a promising anticancer agent for lung cancer treatment.